If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-22. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
==== Intracrine VEGF and cardiac protection ==== The intracrine actions of VEGF have been implicated in cardioprotection, particularly in response to ischemic stress. Cardiac myocytes exposed to hypoxic conditions exhibit increased intracellular VEGF, which appears to play a role in cellular adaptation to oxygen deprivation. This intracrine mechanism promotes the expression of stress-response genes, enhances mitochondrial function, and modulates intracellular calcium signaling, which is critical for maintaining contractility under stress conditions. VEGF has been shown to interact with intracellular angiogenin, another intracrine involved in endothelial cell survival. This interaction establishes a feedback loop where VEGF upregulates angiogenin, which, in turn, enhances VEGF expression. This loop suggests that intracrine VEGF may be a crucial component in the regulation of myocardial vascularization and repair.
National Semiconductor Corporation was an American semiconductor manufacturer, which specialized in analog devices and subsystems, formerly headquartered in Santa Clara, California. The company produced power management integrated circuits, display drivers, audio and operational amplifiers, communication interface products and data conversion solutions. National's key markets included wireless handsets, displays and a variety of broad electronics markets, including medical, automotive, industrial and test and measurement applications. On September 23, 2011, the company formally became part of Texas Instruments as the "Silicon Valley" division.
== Awards and honors == 1988-1990 - Wentink Award for Graduate Student of the Year, Cornell University 1991-1992 - Alexander von Humboldt Fellowship for Study in Germany 1997 - NIH First Award 1998 - NSF Career Award 1998 - Eli Lilly Young Investigator Grantee 1999 - DuPont Young Investigator Award 1999 - Camille Dreyfus Teacher-Scholar Award 2000 - Alfred Sloan Foundation Fellow 2002 - Merck Faculty Development Award 2003-2004 - John Simon Guggenheim Memorial Fellow 2017 - ACS Maryland Chemist of the Year
After losing its status as capital, Moscow's population initially decreased—from 200,000 in the 17th century to 130,000 in 1750. However, after 1750, the population grew tenfold over the remaining duration of the Russian Empire, reaching 1.8 million by 1915. The 1770–1772 Russian plague killed up to 100,000 people in Moscow. By 1700, the construction of cobbled roads had begun. In 1730, permanent street lights were introduced, and by 1867 many streets had a gaslight. In 1883, near the Prechistinskiye Gates, arc lamps were installed. In 1741, Moscow was surrounded by a barricade 40 kilometers (25 mi) long, the Kamer-Kollezhskiy barrier, with 16 gates where customs tolls were collected. The barrier's line is traced in contemporary Moscow by several streets called val ("ramparts"). In the early 19th century, the Arch of Konstantino-Eleninsky Gate was paved with bricks; however, the Spassky Gate was the primary front gate of the Kremlin and was used for royal entrances. From this gate, wooden and stone bridges stretched across the moat. Books were sold on this bridge, and stone platforms were built nearby for guns—"raskats". The Tsar Cannon was located on the Lobnoye mesto platform. The road connecting Moscow with Saint Petersburg—the M10 highway in contemporary Russia—was completed in 1746; the road's Moscow end followed the old Tver road, which had existed since the 16th century. The road became known as Peterburskoye Schosse after being paved in the 1780s. Petrovsky Palace was built in 1776–1780 by architect Matvey Kazakov.
Sources: en.wikipedia.org
== Further reading == Adams, Jad (2004) Hideous absinthe: a history of the devil in a bottle, London: I.B. Tauris. ISBN 1860649203 Arnold, Wilfred Niels (June 1989). "Absinthe". Scientific American. 260 (6): 112–117. Bibcode:1989SciAm.260f.112A. doi:10.1038/scientificamerican0689-112. PMID 2658044. S2CID 215053033. Retrieved 18 September 2010. Blumer, D. (2002). "The Illness of Vincent van Gogh". American Journal of Psychiatry. 159 (4): 519–526. doi:10.1176/appi.ajp.159.4.519. PMID 11925286. S2CID 43106568. Conrad, Barnaby (1996). Absinthe: History in a Bottle. San Francisco: Chronicle Books. ISBN 978-0811816502. Crowley, Aleister (1918). "Absinthe: The Green Goddess" (PDF). The International. XII (2). Archived from the original (PDF) on 18 September 2020. Retrieved 5 March 2016. Eadie, MJ (2009). "Absinthe, epileptic seizures and Valentin Magnan". The Journal of the Royal College of Physicians of Edinburgh. 39 (1): 73–78. doi:10.1177/1478271520093901011. PMID 19831287. Guthrie, R. Winston (2010). A Taste for Absinthe. New York: Clarkson Potter. p. 176. ISBN 978-0307587534. Archived from the original on 28 February 2019. Retrieved 26 September 2012. Huisman, M.; Brug, J.; MacKenbach, J. (2007). "Absinthe is its history relevant for current public health?". International Journal of Epidemiology. 36 (4): 738–744. doi:10.1093/ije/dym068. hdl:1765/36056. PMID 17982755. Lachenmeier, Dirk W.; Nathan-Maister, David; Breaux, Theodore A.; Sohnius, Eva-Maria; Schoeberl, Kerstin; Kuballa, Thomas (2008).
As pH rises above 0 the above yellow hydrolyzed species form and as it rises above 2–3, reddish-brown hydrous iron(III) oxide precipitates out of solution. Although Fe3+ has a d5 configuration, its absorption spectrum is not like that of Mn2+ with its weak, spin-forbidden d–d bands, because Fe3+ has higher positive charge and is more polarizing, lowering the energy of its ligand-to-metal charge transfer absorptions. Thus, all the above complexes are rather strongly colored, with the single exception of the hexaquo ion – and even that has a spectrum dominated by charge transfer in the near ultraviolet region. On the other hand, the pale green iron(II) hexaquo ion [Fe(H2O)6]2+ does not undergo appreciable hydrolysis. Carbon dioxide is not evolved when carbonate anions are added, which instead results in white iron(II) carbonate being precipitated out. In excess carbon dioxide this forms the slightly soluble bicarbonate, which occurs commonly in groundwater, but it oxidises quickly in air to form iron(III) oxide that accounts for the brown deposits present in a sizeable number of streams.
In a general sense, a clinical endpoint is included in the entities of interest in a trial. The results of a clinical trial generally indicate the number of people enrolled who reached the pre-determined clinical endpoint during the study interval compared with the overall number of people who were enrolled. Once a patient reaches the endpoint, he or she is generally excluded from further experimental intervention (the origin of the term endpoint). For example, a clinical trial investigating the ability of a medication to prevent heart attack might use chest pain as a clinical endpoint. Any patient enrolled in the trial who develops chest pain over the course of the trial, then, would be counted as having reached that clinical endpoint. The results would ultimately reflect the fraction of patients who reached the endpoint of having developed chest pain, compared with the overall number of people enrolled. When an experiment involves a control group, the proportion of individuals who reach the clinical endpoint after an intervention is compared with the proportion of individuals in the control group who reached the same clinical endpoint, reflecting the ability of the intervention to prevent the endpoint in question. A clinical trial will usually define or specify a primary endpoint as a measure that will be considered success of the therapy being trialled (e.g. in justifying a marketing approval). The primary endpoint might be a statistically significant improvement in overall survival (OS).
Although the tomato is cooked and eaten as a vegetable, botanically, a tomato is a fruit, specifically a berry, consisting of the ovary, together with its seeds, of a flowering plant. The issue has led to legal dispute in the United States. In 1887, U.S. tariff laws that imposed a duty on vegetables, but not on fruit, caused the tomato's status to become a matter of legal importance. In Nix v. Hedden, the U.S. Supreme Court settled the controversy on 10 May 1893, by declaring that for the purposes of the Tariff of 1883 only, the tomato is a vegetable, based on the popular definition that classifies vegetables by use—they are generally served with dinner and not dessert.
Autoantibodies are usually absent or very low, so instead of being given in standard reference ranges, the values usually denote where they are said to be present, or whether the test is a positive test. There may also be an equivocal interval, where it is uncertain whether there is a significantly increased level.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.